Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc

SG&A Trends: Eli Lilly vs. Perrigo Over a Decade

__timestamp	Eli Lilly and Company	Perrigo Company plc
Wednesday, January 1, 2014	6620800000	675200000
Thursday, January 1, 2015	6533000000	771800000
Friday, January 1, 2016	6452000000	1205500000
Sunday, January 1, 2017	6588100000	1146500000
Monday, January 1, 2018	5975100000	1125800000
Tuesday, January 1, 2019	6213800000	1166100000
Wednesday, January 1, 2020	6121200000	1175500000
Friday, January 1, 2021	6431600000	1111400000
Saturday, January 1, 2022	6440400000	1210100000
Sunday, January 1, 2023	6941200000	1274600000
Monday, January 1, 2024	8593800000

In pursuit of knowledge

A Decade of SG&A: Eli Lilly vs. Perrigo

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. Over the past decade, Eli Lilly and Company and Perrigo Company plc have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking at approximately $6.94 billion in 2023, reflecting a 5% rise from 2014. In contrast, Perrigo's SG&A expenses have grown more significantly, with a 47% increase over the same period, reaching around $1.27 billion in 2023. This divergence highlights Eli Lilly's consistent approach compared to Perrigo's more dynamic adjustments. As these companies navigate the complexities of the pharmaceutical landscape, their SG&A strategies offer valuable insights into their operational priorities and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025